Evropská unie - rumunština - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecții cu hiv - antivirale pentru uz sistemic - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharmathen s.a. - grecia - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pharmathen s.a. - grecia - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

teva pharmaceuticals s.r.l. - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

teva pharmaceuticals s.r.l. - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

famar health care services madrid s.a.u - spania - caspofunginum - pulb. pt. conc. pt. sol. perf. - 50mg - antimicotice de uz sistemic alte antimicotice sistemice

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

famar health care services madrid s.a.u - spania - caspofunginum - pulb. pt. conc. pt. sol. perf. - 70mg - antimicotice de uz sistemic alte antimicotice sistemice

Evropská unie - rumunština - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - agenți antineoplazici - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Moldavsko - rumunština - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

llc rompharm company georgia - caspofunginum - pulbere pentru concentrat pentru soluţie perfuzabilă - 50 mg

Evropská unie - rumunština - EMA (European Medicines Agency)

siga technologies netherlands b.v. - tecovirimat - poxviridae infections; cowpox; monkeypox; vaccinia; smallpox - antivirale pentru uz sistemic - tecovirimat siga is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- smallpox- monkeypox- cowpoxtecovirimat siga is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4. 4 și 5. tecovirimat siga should be used in accordance with official recommendations.